For improving the positive effects of EpFAs in a variety of disorders, including neuropathic pain, hypertension, inflammatory bowel disease, and cardiovascular disease, sEH is thought to be an important therapeutic target [22,23,24,25,26,27]. This evidence concerns the gene EPHX2 and Hypertension.